CD274 and neoplasm: This stability may be due to the fact that treatment decisions regarding PD(L)1i monotherapy in clinical practice are primarily driven by tumor expression of PD‐L1, with high (>50%) PD‐L1 expression receiving pembrolizumab alone as first line treatment.